Invention Grant
US07973031B2 Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
有权
星形孢菌素衍生物作为FLT3受体酪氨酸激酶活性的抑制剂
- Patent Title: Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
- Patent Title (中): 星形孢菌素衍生物作为FLT3受体酪氨酸激酶活性的抑制剂
-
Application No.: US10493786Application Date: 2002-10-29
-
Publication No.: US07973031B2Publication Date: 2011-07-05
- Inventor: James Douglas Griffin , Paul William Manley
- Applicant: James Douglas Griffin , Paul William Manley
- Applicant Address: CH Basel US MA Boston
- Assignee: Novartis AG,Dana-Farber Cancer Institute Inc
- Current Assignee: Novartis AG,Dana-Farber Cancer Institute Inc
- Current Assignee Address: CH Basel US MA Boston
- Agent George R. Dohmann; Kristin E. Konzak; Lydia T. McNally
- International Application: PCT/EP02/12076 WO 20021029
- International Announcement: WO03/037347 WO 20030508
- Main IPC: A61P35/02
- IPC: A61P35/02 ; A61K31/55 ; A61K31/535 ; C07D498/22 ; C07D487/04 ; C07D487/14 ; C07D519/00
Abstract:
The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving deregulated FLT3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodysplastic syndromes, and to a method of treating diseases involving deregulated FLT3 receptor tyrosine kinase activity.
Public/Granted literature
- US20050020570A1 Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity Public/Granted day:2005-01-27
Information query
